Annual Net Income
-$29.36 M
+$29.89 M+50.44%
March 31, 2024
Summary
- As of February 8, 2025, VTGN annual net profit is -$29.36 million, with the most recent change of +$29.89 million (+50.44%) on March 31, 2024.
- During the last 3 years, VTGN annual net income has fallen by -$11.43 million (-63.72%).
- VTGN annual net income is now -326144.44% below its all-time high of -$9000.00, reached on December 31, 2010.
Performance
VTGN Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Net Income
-$12.96 M
-$2.23 M-20.76%
September 30, 2024
Summary
- As of February 8, 2025, VTGN quarterly net profit is -$12.96 million, with the most recent change of -$2.23 million (-20.76%) on September 30, 2024.
- Over the past year, VTGN quarterly net income has stayed the same.
- VTGN quarterly net income is now -7079.54% below its all-time high of $185.70 thousand, reached on June 30, 2013.
Performance
VTGN Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Net Income
-$39.57 M
-$6.37 M-19.20%
September 30, 2024
Summary
- As of February 8, 2025, VTGN TTM net profit is -$39.57 million, with the most recent change of -$6.37 million (-19.20%) on September 30, 2024.
- Over the past year, VTGN TTM net income has stayed the same.
- VTGN TTM net income is now -1798318.18% below its all-time high of -$2200.00, reached on March 31, 2007.
Performance
VTGN TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Net Income Formula
Net Income = Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses
VTGN Net Income Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +50.4% | 0.0% | 0.0% |
| 3 y3 years | -63.7% | 0.0% | 0.0% |
| 5 y5 years | -19.4% | 0.0% | 0.0% |
VTGN Net Income Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -63.7% | +50.4% | -104.1% | +34.5% | -34.8% | +38.6% |
| 5 y | 5-year | -63.7% | +50.4% | -314.5% | +34.5% | -163.9% | +38.6% |
| alltime | all time | <-9999.0% | +50.4% | -7079.5% | +56.1% | <-9999.0% | +38.6% |
VistaGen Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$12.96 M(+20.8%) | -$39.57 M(+19.2%) |
| Jun 2024 | - | -$10.73 M(+12.7%) | -$33.19 M(+13.0%) |
| Mar 2024 | -$29.36 M(-50.4%) | -$9.52 M(+49.9%) | -$29.36 M(-8.4%) |
| Dec 2023 | - | -$6.35 M(-3.6%) | -$32.07 M(-9.6%) |
| Sep 2023 | - | -$6.59 M(-4.6%) | -$35.48 M(-23.5%) |
| Jun 2023 | - | -$6.90 M(-43.5%) | -$46.37 M(-21.7%) |
| Mar 2023 | -$59.25 M(+24.0%) | -$12.23 M(+25.3%) | -$59.25 M(-7.0%) |
| Dec 2022 | - | -$9.76 M(-44.2%) | -$63.71 M(-1.2%) |
| Sep 2022 | - | -$17.48 M(-11.6%) | -$64.48 M(+7.8%) |
| Jun 2022 | - | -$19.78 M(+18.5%) | -$59.79 M(+25.2%) |
| Mar 2022 | -$47.76 M(+166.3%) | -$16.69 M(+58.4%) | -$47.76 M(+28.1%) |
| Dec 2021 | - | -$10.54 M(-17.7%) | -$37.28 M(+16.3%) |
| Sep 2021 | - | -$12.79 M(+65.2%) | -$32.05 M(+42.1%) |
| Jun 2021 | - | -$7.74 M(+24.7%) | -$22.55 M(+25.7%) |
| Mar 2021 | -$17.93 M(-13.7%) | -$6.21 M(+17.2%) | -$17.93 M(+19.6%) |
| Dec 2020 | - | -$5.30 M(+60.7%) | -$14.99 M(-4.2%) |
| Sep 2020 | - | -$3.30 M(+5.5%) | -$15.65 M(-11.5%) |
| Jun 2020 | - | -$3.13 M(-4.3%) | -$17.69 M(-14.8%) |
| Mar 2020 | -$20.77 M(-15.5%) | -$3.27 M(-45.2%) | -$20.77 M(-10.6%) |
| Dec 2019 | - | -$5.96 M(+11.7%) | -$23.23 M(-5.1%) |
| Sep 2019 | - | -$5.34 M(-14.1%) | -$24.49 M(-7.9%) |
| Jun 2019 | - | -$6.21 M(+8.5%) | -$26.59 M(+8.1%) |
| Mar 2019 | -$24.59 M(+71.4%) | -$5.72 M(-20.7%) | -$24.59 M(+7.2%) |
| Dec 2018 | - | -$7.22 M(-2.9%) | -$22.95 M(+22.5%) |
| Sep 2018 | - | -$7.43 M(+76.4%) | -$18.73 M(+15.0%) |
| Jun 2018 | - | -$4.21 M(+3.3%) | -$16.30 M(+13.6%) |
| Mar 2018 | -$14.35 M(+39.9%) | -$4.08 M(+35.7%) | -$14.35 M(+11.9%) |
| Dec 2017 | - | -$3.00 M(-39.9%) | -$12.82 M(+2.9%) |
| Sep 2017 | - | -$5.00 M(+120.6%) | -$12.45 M(+18.0%) |
| Jun 2017 | - | -$2.27 M(-11.1%) | -$10.55 M(+2.9%) |
| Mar 2017 | -$10.26 M(-78.3%) | -$2.55 M(-3.4%) | -$10.26 M(-36.7%) |
| Dec 2016 | - | -$2.64 M(-14.9%) | -$16.21 M(+3.1%) |
| Sep 2016 | - | -$3.10 M(+57.6%) | -$15.72 M(-20.1%) |
| Jun 2016 | - | -$1.97 M(-76.9%) | -$19.66 M(-58.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | -$47.22 M(+240.1%) | -$8.50 M(+296.1%) | -$47.22 M(+5.1%) |
| Dec 2015 | - | -$2.15 M(-69.5%) | -$44.94 M(+2.4%) |
| Sep 2015 | - | -$7.05 M(-76.1%) | -$43.88 M(+12.9%) |
| Jun 2015 | - | -$29.52 M(+374.6%) | -$38.86 M(+179.8%) |
| Mar 2015 | -$13.89 M(+367.9%) | -$6.22 M(+470.6%) | -$13.89 M(+46.3%) |
| Dec 2014 | - | -$1.09 M(-46.0%) | -$9.49 M(+14.8%) |
| Sep 2014 | - | -$2.02 M(-55.6%) | -$8.27 M(+7.3%) |
| Jun 2014 | - | -$4.55 M(+149.6%) | -$7.71 M(+159.7%) |
| Mar 2014 | -$2.97 M(-77.0%) | -$1.82 M(-1492.8%) | -$2.97 M(-39.6%) |
| Dec 2013 | - | $131.00 K(-109.0%) | -$4.91 M(-52.7%) |
| Sep 2013 | - | -$1.46 M(-886.1%) | -$10.38 M(-4.6%) |
| Jun 2013 | - | $185.70 K(-104.9%) | -$10.88 M(-15.6%) |
| Mar 2013 | -$12.89 M(+5.5%) | -$3.77 M(-29.3%) | -$12.89 M(+6.0%) |
| Dec 2012 | - | -$5.33 M(+172.8%) | -$12.16 M(+7.4%) |
| Sep 2012 | - | -$1.96 M(+7.1%) | -$11.32 M(-2.6%) |
| Jun 2012 | - | -$1.83 M(-40.0%) | -$11.62 M(-4.8%) |
| Mar 2012 | -$12.21 M(>+9900.0%) | -$3.04 M(-32.4%) | -$12.21 M(+33.1%) |
| Dec 2011 | - | -$4.50 M(+99.4%) | -$9.17 M(+96.2%) |
| Sep 2011 | - | -$2.26 M(-6.4%) | -$4.67 M(+93.1%) |
| Jun 2011 | - | -$2.41 M(>+9900.0%) | -$2.42 M(>+9900.0%) |
| Mar 2011 | - | -$5300.00(+178.9%) | -$11.40 K(+28.1%) |
| Dec 2010 | -$9000.00(-59.1%) | -$1900.00(-9.5%) | -$8900.00(+6.0%) |
| Sep 2010 | - | -$2100.00(0.0%) | -$8400.00(+10.5%) |
| Jun 2010 | - | -$2100.00(-25.0%) | -$7600.00(0.0%) |
| Mar 2010 | - | -$2800.00(+100.0%) | -$7600.00(-65.5%) |
| Dec 2009 | -$22.00 K(+34.1%) | -$1400.00(+7.7%) | -$22.00 K(-34.5%) |
| Sep 2009 | - | -$1300.00(-38.1%) | -$33.60 K(+3.7%) |
| Jun 2009 | - | -$2100.00(-87.8%) | -$32.40 K(+3.2%) |
| Mar 2009 | - | -$17.20 K(+32.3%) | -$31.40 K(+90.3%) |
| Dec 2008 | -$16.40 K | -$13.00 K(>+9900.0%) | -$16.50 K(+371.4%) |
| Sep 2008 | - | -$100.00(-90.9%) | -$3500.00(+2.9%) |
| Jun 2008 | - | -$1100.00(-52.2%) | -$3400.00(-26.1%) |
| Mar 2008 | - | -$2300.00(0.0%) | -$4600.00(+2.2%) |
| Jun 2007 | - | -$2300.00(+4.5%) | -$4500.00(+104.5%) |
| Mar 2007 | - | -$2200.00 | -$2200.00 |
FAQ
- What is VistaGen Therapeutics annual net profit?
- What is the all time high annual net income for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual net income year-on-year change?
- What is VistaGen Therapeutics quarterly net profit?
- What is the all time high quarterly net income for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly net income year-on-year change?
- What is VistaGen Therapeutics TTM net profit?
- What is the all time high TTM net income for VistaGen Therapeutics?
- What is VistaGen Therapeutics TTM net income year-on-year change?
What is VistaGen Therapeutics annual net profit?
The current annual net income of VTGN is -$29.36 M
What is the all time high annual net income for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual net profit is -$9000.00
What is VistaGen Therapeutics annual net income year-on-year change?
Over the past year, VTGN annual net profit has changed by +$29.89 M (+50.44%)
What is VistaGen Therapeutics quarterly net profit?
The current quarterly net income of VTGN is -$12.96 M
What is the all time high quarterly net income for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly net profit is $185.70 K
What is VistaGen Therapeutics quarterly net income year-on-year change?
Over the past year, VTGN quarterly net profit has changed by $0.00 (0.00%)
What is VistaGen Therapeutics TTM net profit?
The current TTM net income of VTGN is -$39.57 M
What is the all time high TTM net income for VistaGen Therapeutics?
VistaGen Therapeutics all-time high TTM net profit is -$2200.00
What is VistaGen Therapeutics TTM net income year-on-year change?
Over the past year, VTGN TTM net profit has changed by $0.00 (0.00%)